Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
When considering what to eat on Mounjaro or other GLP-1 therapies, focus should shift toward smaller, nutrient-dense portions that prioritise lean proteins and high-fibre vegetables
These immune cells recognise the beta-glucan and become activated, producing growth factors and cytokines which aid in skin healing
Clinical trials show that 2550% of patients experience nausea during dose escalation, though most side effects resolve within 48 weeks as the body adapts
Wie nu wil werken aan een gezonder gewicht, doet er goed aan te kiezen voor een veilige, persoonlijke en medisch begeleide aanpak
A new pathway to access Wegovy for obesity The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight-management drugs for Medicare Part D beneficiaries Medicare GLP-1 Bridge Program Eligible patients can access all doses of Wegovy pill and pen for only Starting July 1, 2026 1 Medicare GLP-1 Bridge Program eligibility 1 Medication prescribed for weight management, in combination with current and ongoing lifestyle modification consistent with the applicable FDA-approved label Enrolled in a Medicare Part D plan (stand-alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types 18 years of age BMI 35 kg/m 2 or BMI 30 kg/m 2 + 1 or more of the following comorbidities Uncontrolled HTN, HFpEF, CKD Stage 3a, or above or BMI 27 kg/m 2 + 1 or more comorbidities Pre-diabetes, previous stroke/MI, symptomatic PAD Terms apply
